alexa Melatonin as an Anti-angiogenetic, Immunomodulatory and Antitumoral Agent | OMICS International
Journal of Tumour Research & Reports
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Melatonin as an Anti-angiogenetic, Immunomodulatory and Antitumoral Agent

Kubilay Dogan Kilic1, Yigit Uyanikgil1,2, Emel Oyku Cetin3 and Mehmet Turgut4*

1Department of Histology and Embryology, Ege University, School of Medicine, Izmir, Turkey

2Cord Blood, Cell-tissue Research and Application Center, Ege University, Izmir, Turkey

3Department of Biopharmaceutics and Pharmacokinetics, Ege University, Izmir, Turkey

4Department of Neurosurgery, Adnan Menderes University School of Medicine, Aydin, Turkey

*Corresponding Author:
Mehmet Turgut
Associate Professor of Neurosurgery, Department of Neurosurgery
Adnan Menderes University School of Medicine, 09100 Aydın
Turkey, 1410 Laney Walker Blvd, CN3124A, Augusta, GA 30912, USA
Tel: +90 256 2134874
Fax: +90 256 2120146
E-mail: [email protected]

Received date: June 08, 2016; Accepted date: June 09, 2016; Published date: June 15, 2016

Citation: Kilic KD, Uyanikgil Y, Cetin EO, Turgut M (2016) Melatonin as an Anti-angiogenetic, Immunomodulatory and Antitumoral Agent. J Brain Tumors Neurooncol 1:e102. doi: 10.4172/2475-3203.1000e102

Copyright: © 2016 Kilic KD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Tumour Research & Reports


Today, it is well-known that melatonin (N-acetyl-5- methoxytryptamine) which is a hormone secreted from pineal gland has oncostatic properties, specifically on hormone-dependent ones. Due to the variation of wide impact of melatonin mechanism, it has diverse courting with antitumor. In fact, this effect is a result of its anti-angiogenetic effects [1]. Furthermore, antitumor activity of the melatonin may be explained its immunomodulatory, anti-proliferative and anti-oxidant effects. Vascular Endothelial Growth Factor (VEGF) is the most angiogenisc element and related to the diagnosis of most cancers. There are capable studies that investigated the impact of melatonin on angiogenesis; Lissoni et al. have evaluated the effects of melatonin remedy on VEGF blood ranges in advanced stage patients via displaying that it has function as a natural anti-angiogenic molecule with angiogenesis-dependent cancers proliferation [2]. Afterwards, Mias et al. applied ex vivo pre-treatment with melatonin to enhance survival, paracrine activity, and efficiency of Mesenchymal Stem Cells (MSCs). Their acute renal failure survival rate of rats strongly expanded after MSC pre-treatment. This effect came with over stimulation of angiogenesis and proliferation of renal cells [3].

Angiogenesis is associated with tumor development, an important process. As long as tumors enlarge, diffusion distances from the prevailing vascular deliver increases and it reasons hypoxia for most cancers cells. Tumor proliferation and migration calls for vascularisation to feed and guide tumor cells with additives. The key regulator of hypoxia triggered angiogenesis is hypoxia inducible factor (HIF)-1. HIF-1 alpha is stabilized with the aid of hypoxia triggered reactive oxygen species (ROS) and uprises the expression of hypoxic genes, consisting of VEGF. In their study Park et al. observed that melatonin destabilizes hypoxia-prompted HIF-1 alpha protein tiers in colon for most cancer cells [4]. This destabilization of HIF-1 alpha resulted from the antioxidant activity of melatonin against ROS brought on by means of hypoxia [4]. Those findings advocate that melatonin may play a lead position in tumor suppression through HIF-1-mediated angiogenesis inhibition [4].

In order to support the relation between melatonin and VEGF, the study of Dai et al. is important [5]. They stated that physiologic concentrations of melatonin don't have any apparent impact on the VEGF expression, however, pharmacologic concentrations of melatonin suppress the VEGF mRNA and protein degrees brought about by hypoxia echoer cobalt chloride (CoCl2) [5]. Melatonin also decreases HIF-1 alpha protein levels. Their data display that melatonin in excessive concentration markedly reduces the expression of endogenous VEGF and HIF-1 alpha-induced via CoCl2 in different types of cultured cancers cells [5].

Gathering information together indicates that oxidative stress performs a fundamental function in regulating the activity of Matrix Metalloproteinases (MMPs) which might be involved in several cellular processes include angiogenesis [6]. Melatonin induces apoptosis in liver cancer and suggests anti-angiogenic effect in numerous tumors. Carbajo-Pescador et al. used human HepG2 liver cancer cells as an in vitro model to investigate the anti-angiogenic consequences of melatonin [7]. They suggested that melatonin exerts an anti-angiogenic activity in HepG2 cells by interfering the transcriptional activation of VEGF, thru HIF1 alpha and STAT3 [7]. Results offer evidence to recollect this indole as a strength anti-angiogenic agent for hepatocellullar carcinoma treatment [7].

In conclusion, melatonin in high concentration can markedly reduce the Human Umbilical Vein Endothelial Cells (HUVEC) proliferation and induce cellular apoptosis Moreover can decrease the cell cycle length by modulating p53 and Bax/Bcl-2 expression. Treatment with melatonin may be an innovative and challenging therapy for cancer anti-angiogenesis therapeutics. In the future, most cancers therapy protocols embedded with low concentrations of melatonin can put a light for further investigations for anti-angiogenic process. Melatonin in high concentration can markedly reduce the HUVEC proliferation while setting off apoptosis with modulating p53 and Bax/Bcl-2 expression during cell cycle. Now, we strongly believe that treatment with melatonin may be a revolutionary and tough remedy for anti-angiogenic cancer therapy [8]. The wound healing is an angiogenesis-dependent process. Post wounding HO-2 protein levels barely increase in both the control and melatonin treatment group. In a study, melatonin treatment group shows that a further increase (although not significant) in HO-2 protein levels and supported healing through angiogenesis [9]. Melatonin induces the production of interleukin-1, Tumor Necrosis Factor (TNF)-α and Transforming Growth Factor (TGF) cytokines. Additionally it is an immunomodulator and a neuroendocrine hormone which stimulates monocyte cytokine and fibroblast proliferation in angiogenic process. Recent studies have determined that melatonin can also have a positive effect on both angiogenesis and wound healing [10]. In a recent study, melatonin increased angiogenesis which has relation with the refinement of MMP-2 expression and activity and also upregulation of VEGF in rat cornea. Melatonin shielded from gastric lesions by upraising angiogenesis thru upregulation of VEGF accompanied with the support of over-expression of MMP-2. It showed that melatonin exerts angiogenesis thru MMP-2 and VEGF over-expression all through safety and recuperation of gastric ulcers [11].


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 2nd World Congress on Embryology and In Vitro Fertilization March 30-31, 2018 Orlando, USA
    March 30-31, 2018 Orlando, USA
  • Annual Physicians Meeting 2018 May 11-12, 2018 Osaka, Japan
    May 11-12, 2018 Osaka, Japan
  • International Conference on Internal Medicine May 21-22, 2018 Osaka, Japan
    May 21-22, 2018 Osaka, Japan
  • 3rd International Conference on Anesthesia June 21-22, 2018 Dublin, Ireland
    June 21-22, 2018 Dublin, Ireland
  • Annual Congress on Research and Innovations in Medicine July 02-03, 2018 Bangkok, Thailand
    July 02-03, 2018 Bangkok, Thailand

Article Usage

  • Total views: 8297
  • [From(publication date):
    June-2016 - Mar 21, 2018]
  • Breakdown by view type
  • HTML page views : 8192
  • PDF downloads : 105

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version